NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date and time:** Wednesday 5 October 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Stephen Smith (Vice-chair) Present for all items
3. Martin Bradley Present for all items
4. Professor Sofia Dias Present for all items
5. Professor Rachel Elliott Items 1 to 5.2.2
6. Christopher Herring Present for all items
7. Dr Andrew Hitchings Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Present for all items
10. Dr Ivan Koychev Present for all items
11. Dr Soo Fon Lim Present for all items
12. Dr Guy Makin Present for all items
13. Dr Philip Mallender Present for all items
14. Professor David Meads Present for all items
15. Giles Monnickendam Present for all items
16. Dr Malcolm Oswald Present for all items
17. Dr Rebecca Payne Items 1 to 4.1.3 & 5 to 6.2.2
18. Carole Pitkeathley Present for all items
19. Dr Raju Reddy Present for all items
20. Professor John Watkins Present for all items

NICE staff (key players) present

Ross Dent, Associate Director Items 1 to 5.2.2

Linda Landells, Associate Director Items 1 to 5.2.2

Jasdeep Hayre, Associate Director Items 6 to 6.2.2

Louise Jafferally, Project Manager Items 1 to 4.2.2

Kate Moore, Project Manager Items 5 to 5.2.2

Celia Mayers, Project Manager Items 6 to 6.2.2

Fatima Chunara, Heath Technology Assessment Adviser Items 1 to 5.2.2

Caron Jones, Heath Technology Assessment Adviser Items 1 to 5.2.2

Adam Brooke, Heath Technology Assessment Adviser Items 6 to 6.2.2

Alex Sampson, Heath Technology Assessment Analyst Items 1 to 5.2.2

Lizzie Walker, Heath Technology Assessment Analyst Items 4.1.3 to 5.2.2

Elizabeth Bell, Heath Technology Assessment Analyst Items 6 to 6.2.2

Maroulla Whiteley, Business Analyst, RIA Present for all items

Helen Barnett, Senior Medical Editor Items 1 to 5.2.2

Olivia Havercroft, Senior Medical Editor Items 6 to 6.2.2

Emma Gordon, Coordinator, MIP Items 1 to 4.1.3 & 6 to 6.1.3

Rosalee Mason, Coordinator, MIP Items 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Items 1 to 4.2.2

Mohammed Towhasir, Administrator, TA Items 5 to 5.2.2

Leah Kelly, Administrator, TA Items 6 to 6.2.2

NICE staff (observers) present

Oyewumi Afolabi, Technical Analyst, PASLU Items 1 to 5.2.2

Catrin Austin, Technical Analyst, Methods, and Economics Present for all items

Matthew Brown, Digital Media Manager Items 6.1.3 to 6.2.2

Stephen Duffield, Senior Analyst, Data and Analytics Items 1 to 4.2.2

Neha Jiandani, Technical Analyst, Commercial Liaison Items 6 to 6.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 6 to 6.2.2

Stephen Norton, Technical Analyst, Managed Access Items 6.1.3 to 6.2.2

Thomas Palmer, Technical Analyst, Managed Access Items 6 to 6.2.2

Benjamin Purchase, Senior Scientific Adviser Items 6 to 6.2.2

External assessment group representatives present

Nigel Armstrong, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3 & 5 to 5.1.3

Willem Witlox, Kleijnen Systematic Reviews Ltd (KSR) Items 1 to 4.1.3 & 5 to 5.1.3

NHS England expert present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 1 to 5.2.2

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 7 September 2022.

### Appraisal of amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3836]

* 1. Part 1 – Open session
		1. The chair welcomed the invited, CDF clinical lead, external assessment group representatives, members of the public and company representatives from Janssen.
		2. The chair asked all committee members, external assessment group representatives, CDF clinical lead, and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared an indirect financial interest as the University of Leeds has received funding from Janssen and BMS for research in an unrelated area. It was agreed that his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Ivan Koychev declared an indirect financial interest as he has a collaboration with Johnson and Johnson in an unrelated area (Alzheimer's disease) as part of which they are investigating blood biomarkers for Alzheimer's disease. He also declared indirect financial interest, due to having a past collaboration with Roche as part of which digital technologies were developed for the detection of cognitive impairment in ageing adults, which has now concluded. It was agreed that his declaration would not prevent Dr Koychev from participating in discussions on this appraisal
* Committee member Dr Matthew Bradley declared financial interests as he holds shares in AstraZeneca, a potential comparator manufacturer. As a direct conflict Dr Bradley did not participate in discussion of this appraisal.
* No further interests were declared for this appraisal.
	+ 1. The chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10729>,.

### Appraisal of mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3984]

* 1. Part 1 – Open session
		1. The chair Dr Megan John welcomed the invited CDF clinical lead, external assessment group representatives, members of the public and company representatives from Takeda.
		2. The chair asked all committee members, external assessment group representatives, CDF clinical lead and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared an indirect financial interest as the University of Leeds has received funding from Janssen and BMS for research in an unrelated area. It was agreed that his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Matthew Bradley declared financial interests as he holds shares in AstraZeneca, a potential comparator manufacturer. As a direct conflict Dr Bradley did not participate in discussion of this appraisal.
* No further interests were declared for this appraisal.
	+ 1. The chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10881>

### Appraisal of esketamine for treatment-resistant depression [ID1414]

* 1. Part 1 – Open session
		1. The chair Dr Megan John welcomed, external assessment group representatives, members of the public and company representatives from Janssen
		2. The chair asked all committee members, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared an indirect financial interest as the University of Leeds has received funding from Janssen for research in an unrelated area. It was agreed that his declaration would not prevent Professor Meads from participating in discussions on this appraisal.
* Committee member Dr Ivan Koychev declared professional and financial interests as he has a collaboration with Janssen as part of which blood samples are analysed for biomarkers of neurodegeneration free of charge. The Oxford Department of Psychiatry has received funding from Janssen for an observational study in treatment resistant depression. He was not involved in the study. It was agreed that his declaration would not prevent Dr Koychev from participating in discussions on this appraisal
* Committee member Dr Matthew Bradley declared financial interests as he is an employee of GSK and hold shares in AstraZeneca, both companies are identified as potential competitors for esketamine. As a direct conflict Dr Bradley did not participate in discussion of this appraisal.
* Committee member Professor Rachel Elliott declared financial interests as she received a payment of £200 on 18/08/20 from Janssen for one hour’s discussion on depression treatments. As a direct conflict Professor Elliott did not participate in discussion of this appraisal.
* No further interests were declared for this appraisal.
	+ 1. The chair led a discussion of the consultation comments presented to the committee.
	1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10371>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 2 November 2022 and will start promptly at 09.30.